Petosemtamab is under clinical development by Merus and currently in Phase II for Oral Cavity (Mouth) Cancer. According to GlobalData, Phase II drugs for Oral Cavity (Mouth) Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Petosemtamab LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Petosemtamab overview
Petosemtamab (MCLA-158) is under development for the treatment of metastatic colorectal cancer and other solid tumors including non-small cell lung cancer, squamous non-small cell lung cancer, gastric cancer, pancreatic cancer, salivary gland cancer, squamous esophageal cancer and recurrent head and neck squamous cell carcinoma. The therapeutic candidate is administered through intravenous route. It is a bi-specific monoclonal antibody which acts by targeting leucine rich repeat containing G protein-coupled receptor 5 (LGR5) and epidermal growth factor receptor (EGFR). The therapeutic candidate is developed based on ADCC-Biclonics technology platform.
It was also under development for the treatment of adenocarcinoma of the gastroesophageal junction, cervical cancer, vaginal cancer, vulvar cancer, penile cancer, anal cancer.
Merus overview
Merus is a clinical-stage oncology company that develops innovative antibody therapeutics. The company utilizes the Multiclonics, Biclonics and Triclonics platforms to develop human bispecific and tri-specific antibodies. Its pipeline products include petosemtamab (MCLA-158), a low-fucose human full-length IgG1 antibody that targets head and neck squamous cell carcinoma (HNSCC); MCLA-129 and MCLA-145 targeting advanced non-small cell lung cancer (NSCLC) and solid tumors; Zenocutuzumab (MCLA-128), antibody-dependent cell-mediated cytotoxicity (ADCC) drug for non-small cell lung cancer and pancreatic cancer; ONO-4685 for refractory T cell lymphoma and psoriasis; and INCA32459 and INCA33890 for advanced malignancies and select advanced solid tumors. The company operates through its subsidiaries in the Netherlands and the US. Merus is headquartered in Utrecht, the Netherlands.
For a complete picture of Petosemtamab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.